Genmab — November 2016
-
-
-
deal done Actilion
-
sorry sukkeralf, fik den some deal done, så ændrede overskriften sig, ved ikke lige, hvad der sker
-
2 sec
-
ZURICH, Nov 29 (Reuters) - Shares in Swiss biotech company Actelion ATLN.S plunged on Tuesday after a report the company was not actively considering selling itself, but instead weighing a "complicated deal" to link with U.S. healthcare giant Johnson & Johnson JNJ.N.
Actelion shares fell more than 8 percent in early trading, after having risen sharply over the last four days to value the company at about $20 billion amid takeover speculation. (Full Story)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind